Paper. Pagni BA, Ross S, Mennenga S et al.. Drug and Alcohol Dependence, 15 Oct 2026.
Tags: Human, RCT, Psilocybin, Addiction.
Open-label psilocybin after an AUD trial helped mainly the heaviest drinkers, and a sex-difference reanalysis found little.
Fifty-nine adults who completed the NYU alcohol trial got one open-label 25-40 mg/70kg dose; gains in heavy drinking days concentrated in those still drinking heavily at entry, with no serious adverse events. Separately, a Bayesian reanalysis of the 59-person psilocybin-vs-escitalopram trial found no overall sex difference, with a single signal: lower post-treatment anxiety in women on psilocybin.
How much weight it carries: Open-label extension of a phase 2 RCT with no blinded comparator, plus a post hoc Bayesian reanalysis with only 20 women; both are secondary, not confirmatory. (Humans, Open-label, No control group, Small sample, n = 59)
